Section Arrow
ZLAB.NASDAQ
- Zai Lab Limited
Quotes are at least 15-min delayed:2024/05/16 12:07 EDT
Last
 20.065
-0.785 (-3.76%)
Day High 
20.39 
Prev. Close
20.85 
1-M High
22.35 
Volume 
239.69K 
Bid
20
Ask
20.1
Day Low
19.42 
Open
20.39 
1-M Low
13.48 
Market Cap 
2.06B 
Currency USD 
P/E -- 
%Yield
10-SMA 18.8 
20-SMA 17.08 
50-SMA 16.93 
52-W High 37.92 
52-W Low 13.48 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.50/-0.24
Enterprise Value
2.07B
Balance Sheet
Book Value Per Share
7.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
266.72M
Operating Revenue Per Share
2.67
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.09995+0.02225+28.64%-- 
DNAGinkgo Bioworks Holdings0.8301-0.009-1.07%-- 
JAGXJaguar Health0.2662+0.0111+4.35%-- 
NBYNovaBay Pharmaceuticals0.115+0.0105+10.05%-- 
NVAXNovavax13.3901+0.4901+3.80%-- 
Quotes are at least 15-min delayed:2024/05/16 12:07 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.